orphenadrine has been researched along with piperidines in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bersani, G; Ciani, N; Grispini, A; Marini, S; Pasini, A; Valducci, M | 1 |
| Costall, B; Naylor, RJ | 1 |
| Carbonara, R; Conte Camerino, D; Costanza, T; Desaphy, JF | 1 |
1 trial(s) available for orphenadrine and piperidines
| Article | Year |
|---|---|
5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Orphenadrine; Parkinson Disease, Secondary; Piperidines; Psychiatric Status Rating Scales; Ritanserin; Serotonin Antagonists | 1990 |
2 other study(ies) available for orphenadrine and piperidines
| Article | Year |
|---|---|
The relationship between the inhibition of dopamine uptake and the enhancement of amphetamine stereotypy.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Chlorpheniramine; Dopamine; Dopamine Antagonists; Drug Synergism; Histamine H1 Antagonists; Injections, Intraperitoneal; Male; Orphenadrine; Parasympatholytics; Parkinson Disease; Piperidines; Rats; Trihexyphenidyl | 1971 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle, Skeletal; Myotonia Congenita; Orphenadrine; Piperidines; Propafenone; Rats; Rats, Wistar; Riluzole; Sodium Channel Blockers; Thiazoles | 2014 |